Covered recipient · General Payments record
LINDSAY S ACKERMAN
Allopathic & Osteopathic Physicians Dermatology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2019 · Entire year
$130,412.01
187 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2019 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $58,907.50 | 17 |
| Consulting Fee | $30,692.50 | 9 |
| Honoraria | $26,400.00 | 5 |
| Travel and Lodging | $10,786.38 | 45 |
| Food and Beverage | $3,537.90 | 109 |
| Education | $87.73 | 2 |
By paying entity
PY2019 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| AbbVie, Inc. | $74,542.16 | 85 |
| Sun Pharmaceutical Industries Inc. | $30,232.62 | 25 |
| Janssen Biotech, Inc. | $13,142.10 | 18 |
| Helsinn Therapeutics (U.S.), Inc. | $4,881.13 | 5 |
| Amgen Inc. | $3,872.05 | 6 |
| Ortho Dermatologics, a division of Bausch Health US, LLC | $2,481.18 | 10 |
| Celgene Corporation | $575.10 | 12 |
| Regeneron Healthcare Solutions, Inc. | $259.91 | 5 |
| Genentech USA, Inc. | $98.32 | 5 |
| Johnson & Johnson Health Care Systems Inc. | $60.05 | 1 |
| DUSA Pharmaceuticals, Inc. | $47.23 | 2 |
| Lilly USA, LLC | $43.65 | 3 |
| PruGen, Inc. Pharmaceuticals | $41.54 | 3 |
| Biofrontera Inc. | $37.45 | 2 |
| UCB, Inc. | $22.22 | 1 |
| LEO Pharma Inc. | $21.94 | 1 |
| SANOFI-AVENTIS U.S. LLC | $19.50 | 1 |
| Merck Sharp & Dohme Corporation | $18.31 | 1 |
| PFIZER INC. | $15.55 | 1 |
Page 4 of 4; records 151–187 of 187 matching records. This page contains 37 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
LINDSAY S ACKERMAN
NPI 1609900299 · CMS profile ID 27818
Allopathic & Osteopathic Physicians / Dermatology
PHOENIX, AZ
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 4 of 4; records 151–187 of 187 matching records. This page contains 37 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1609900299?year=2019&recipient=provider&page=4#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- LINDSAY S ACKERMAN, NPI 1609900299, CMS profile ID 27818. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 4; records 151–187 of 187 matching records. This page contains 37 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1609900299?year=2019&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- APA 7
- IndustryPayments. (2026). LINDSAY S ACKERMAN, NPI 1609900299, CMS profile ID 27818. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 4; records 151–187 of 187 matching records. This page contains 37 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1609900299?year=2019&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- Bluebook
- LINDSAY S ACKERMAN, NPI 1609900299, CMS profile ID 27818, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 4 of 4; records 151–187 of 187 matching records. This page contains 37 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1609900299?year=2019&recipient=provider&page=4#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2019
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30
187 matching records · $130,412.01 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 151–187 of 187.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| AbbVie, Inc. | $2,275.00 | 03/21/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 647779449 | CMS |
| Helsinn Therapeutics (U.S.), Inc. | $2,667.50 | 03/21/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 655943917 | CMS |
| AbbVie, Inc. | $110.00 | 03/20/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 647779453 | CMS |
| AbbVie, Inc. | $345.24 | 03/20/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 647779461 | CMS |
| AbbVie, Inc. | $5,200.00 | 03/19/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 647779485 | CMS |
| Celgene Corporation | $2.82 | 03/18/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 672759795 | CMS |
| AbbVie, Inc. | $5.97 | 03/13/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 647779451 | CMS |
| Sun Pharmaceutical Industries Inc. | $6,000.00 | 03/11/2019 | Honoraria | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 704590691 | CMS |
| Sun Pharmaceutical Industries Inc. | $1,155.09 | 03/11/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 704590693 | CMS |
| Sun Pharmaceutical Industries Inc. | $246.33 | 03/11/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 704590695 | CMS |
| Sun Pharmaceutical Industries Inc. | $70.31 | 03/11/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 704590697 | CMS |
| Biofrontera Inc. | $16.46 | 03/04/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 687913939 | CMS |
| AbbVie, Inc. | $4.13 | 03/03/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 647779515 | CMS |
| SANOFI-AVENTIS U.S. LLC | $19.50 | 03/03/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 693964765 | CMS |
| Janssen Biotech, Inc. | $67.38 | 03/02/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658292601 | CMS |
| Johnson & Johnson Health Care Systems Inc. | $60.05 | 03/01/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 644342574 | CMS |
| Lilly USA, LLC | $14.50 | 02/26/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 657975891 | CMS |
| Genentech USA, Inc. | $19.49 | 02/21/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 681270531 | CMS |
| Celgene Corporation | $2.47 | 02/20/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 672759706 | CMS |
| AbbVie, Inc. | $1,300.00 | 01/31/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 647779445 | CMS |
| AbbVie, Inc. | $24.30 | 01/29/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 647779447 | CMS |
| Celgene Corporation | $5.34 | 01/23/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 672714657 | CMS |
| Sun Pharmaceutical Industries Inc. | $6,000.00 | 01/23/2019 | Honoraria | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 704590673 | CMS |
| Sun Pharmaceutical Industries Inc. | $710.28 | 01/23/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 704590675 | CMS |
| Sun Pharmaceutical Industries Inc. | $215.84 | 01/23/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 704590677 | CMS |
| Sun Pharmaceutical Industries Inc. | $35.50 | 01/23/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 704590679 | CMS |
| Sun Pharmaceutical Industries Inc. | $23.33 | 01/23/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 704590681 | CMS |
| Sun Pharmaceutical Industries Inc. | $8,800.00 | 01/23/2019 | Honoraria | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 704590683 | CMS |
| Sun Pharmaceutical Industries Inc. | $25.00 | 01/23/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 704590685 | CMS |
| Sun Pharmaceutical Industries Inc. | $23.32 | 01/23/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 704590687 | CMS |
| Sun Pharmaceutical Industries Inc. | $12.23 | 01/23/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 704590689 | CMS |
| Sun Pharmaceutical Industries Inc. | $35.50 | 01/23/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 704590713 | CMS |
| Genentech USA, Inc. | $19.71 | 01/15/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 681151239 | CMS |
| Ortho Dermatologics, a division of Bausch Health US, LLC | $16.67 | 01/04/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 684565103 | CMS |
| AbbVie, Inc. | $54.00 | 01/03/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 647779583 | CMS |
| AbbVie, Inc. | $7,800.00 | 01/03/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 647779585 | CMS |
| AbbVie, Inc. | $30.84 | 01/03/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 647779587 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $1,128,315.86 | 303 |
| PY2024 | Recipient | $9,104.58 | 2 |
| PY2024 | Principal investigator | $1,402,000.34 | 351 |
| PY2023 | Recipient | $1,216.57 | 9 |
| PY2023 | Principal investigator | $1,090,856.71 | 307 |
| PY2022 | Principal investigator | $969,713.61 | 162 |
| PY2021 | Principal investigator | $922,895.00 | 86 |
| PY2020 | Recipient | $43.62 | 1 |
| PY2020 | Principal investigator | $257,398.28 | 37 |
| PY2019 | Principal investigator | $53,058.99 | 30 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
303 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | ABBVIE INC. | $4,380.00 | 12/31/2025 | Non-covered Recipient Entity SOUTHWEST SKIN SPECIALISTS LLC | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202535219 |
| Principal investigator 1 | ABBVIE INC. | $6,010.00 | 12/30/2025 | Non-covered Recipient Entity SOUTHWEST SKIN SPECIALISTS LLC | Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis | No dispute reported | 06/30/2026 | 1202532162 |
| Principal investigator 1 | ABBVIE INC. | $7,020.00 | 12/30/2025 | Non-covered Recipient Entity SOUTHWEST SKIN SPECIALISTS LLC | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202532172 |
| Principal investigator 1 | Incyte Corporation | $1,500.00 | 12/24/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS PHOENIX | A Phase 3, Double-Blinded, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Prurigo Nodularis | No dispute reported | 06/30/2026 | 1240553650 |
| Principal investigator 1 | Incyte Corporation | $1,500.00 | 12/24/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS PHOENIX | A Phase 3, Double-Blinded, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Prurigo Nodularis | No dispute reported | 06/30/2026 | 1240553656 |
| Principal investigator 1 | Incyte Corporation | $3,500.00 | 12/24/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS PHOENIX | A Phase 3, Double-Blinded, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Prurigo Nodularis | No dispute reported | 06/30/2026 | 1240553728 |
| Principal investigator 1 | Incyte Corporation | $1,000.00 | 12/24/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS PHOENIX | A Phase 3, Double-Blinded, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Prurigo Nodularis | No dispute reported | 06/30/2026 | 1240553794 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $2,000.00 | 12/22/2025 | Non-covered Recipient Entity Oliver Street Dermatology Managemen U S Dermatology Partners Southwest Skin Specialists Llc | A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel Group, Proof-of-concept Study Assessing the Efficacy and Safety of Amlitelimab in Adult Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1226156739 |
| Principal investigator 1 | Incyte Corporation | $1,736.00 | 12/19/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS PHOENIX | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240553686 |
| Principal investigator 1 | Incyte Corporation | $1,510.00 | 12/19/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS PHOENIX | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240553692 |
| Principal investigator 1 | Incyte Corporation | $47.00 | 12/19/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS PHOENIX | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240553710 |
| Principal investigator 1 | Incyte Corporation | $47.00 | 12/19/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS PHOENIX | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240553716 |
| Principal investigator 1 | Incyte Corporation | $1,659.00 | 12/19/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS PHOENIX | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240553752 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $219.00 | 12/17/2025 | Non-covered Recipient Entity US Dermatology Partners-Phoenix | A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy | No dispute reported | 06/30/2026 | 1220760141 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $7.20 | 12/17/2025 | Non-covered Recipient Entity US Dermatology Partners-Phoenix | A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy | No dispute reported | 06/30/2026 | 1220760143 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $65.55 | 12/17/2025 | Non-covered Recipient Entity US Dermatology Partners-Phoenix | A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy | No dispute reported | 06/30/2026 | 1220760145 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $70.38 | 12/17/2025 | Non-covered Recipient Entity US Dermatology Partners-Phoenix | A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy | No dispute reported | 06/30/2026 | 1220760147 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $10.50 | 12/17/2025 | Non-covered Recipient Entity US Dermatology Partners-Phoenix | A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy | No dispute reported | 06/30/2026 | 1220760149 |
| Principal investigator 1 | Incyte Corporation | $10,772.00 | 12/08/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS PHOENIX | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240553722 |
| Principal investigator 1 | Incyte Corporation | $2,250.00 | 12/08/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS PHOENIX | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240553740 |
| Principal investigator 1 | ABBVIE INC. | $7,769.00 | 12/04/2025 | Non-covered Recipient Entity SOUTHWEST SKIN SPECIALISTS LLC | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202527224 |
| Principal investigator 1 | ABBVIE INC. | $2,500.00 | 12/04/2025 | Non-covered Recipient Entity SOUTHWEST SKIN SPECIALISTS LLC | Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis | No dispute reported | 06/30/2026 | 1202527430 |
| Principal investigator 1 | ABBVIE INC. | $23,038.40 | 12/04/2025 | Non-covered Recipient Entity SOUTHWEST SKIN SPECIALISTS LLC | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202527432 |
| Principal investigator 1 | Incyte Corporation | $757.80 | 12/04/2025 | Non-covered Recipient Entity SOUTHWEST SKIN SPECIALISTS PHOENIX BILTMORE | Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib | No dispute reported | 06/30/2026 | 1240592819 |
| Principal investigator 1 | Incyte Corporation | $1.02 | 12/01/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS PHOENIX | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240553626 |
| Principal investigator 1 | Incyte Corporation | $33.18 | 12/01/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS PHOENIX | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240553632 |
| Principal investigator 1 | Incyte Corporation | $11.85 | 12/01/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS PHOENIX | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240553638 |
| Principal investigator 1 | Incyte Corporation | $7.11 | 12/01/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS PHOENIX | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240553644 |
| Principal investigator 1 | Incyte Corporation | $18.96 | 12/01/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS PHOENIX | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240553662 |
| Principal investigator 1 | Incyte Corporation | $16.59 | 12/01/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS PHOENIX | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240553668 |
| Principal investigator 1 | Incyte Corporation | $16.59 | 12/01/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS PHOENIX | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240553674 |
| Principal investigator 1 | Incyte Corporation | $16.59 | 12/01/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS PHOENIX | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240553680 |
| Principal investigator 1 | Incyte Corporation | $47.40 | 12/01/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS PHOENIX | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240553734 |
| Principal investigator 1 | Incyte Corporation | $9.48 | 12/01/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS PHOENIX | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240553770 |
| Principal investigator 1 | Incyte Corporation | $2.37 | 12/01/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS PHOENIX | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240553806 |
| Principal investigator 1 | Incyte Corporation | $2.37 | 12/01/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS PHOENIX | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240553811 |
| Principal investigator 1 | Incyte Corporation | $1,373.40 | 11/24/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS PHOENIX | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240553698 |
| Principal investigator 1 | Incyte Corporation | $79.00 | 11/21/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS PHOENIX | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240553704 |
| Principal investigator 1 | Incyte Corporation | $2,426.00 | 11/21/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS PHOENIX | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240553776 |
| Principal investigator 1 | Incyte Corporation | $2,426.00 | 11/21/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS PHOENIX | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240553782 |
| Principal investigator 1 | Incyte Corporation | $9,000.00 | 11/10/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS PHOENIX | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240553746 |
| Principal investigator 1 | Incyte Corporation | $3,000.00 | 11/10/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS PHOENIX | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240553800 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $58,121.87 | 11/10/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS | 24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years S | No dispute reported | 06/30/2026 | 1190309742 |
| Principal investigator 1 | ABBVIE INC. | $650.75 | 11/05/2025 | Non-covered Recipient Entity SOUTHWEST SKIN SPECIALISTS LLC | Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis | No dispute reported | 06/30/2026 | 1202521669 |
| Principal investigator 1 | ABBVIE INC. | $7,958.60 | 11/05/2025 | Non-covered Recipient Entity SOUTHWEST SKIN SPECIALISTS LLC | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202521671 |
| Principal investigator 1 | ARGENX US, INC. | $750.00 | 11/05/2025 | Non-covered Recipient Entity SOUTHWEST SKIN SPECIALISTS LLC | An Open-label Extension Study of ARGX-113-2009 to Evaluate the Long term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid | No dispute reported | 06/30/2026 | 1237157626 |
| Principal investigator 1 | ARGENX US, INC. | $2,000.00 | 11/05/2025 | Non-covered Recipient Entity SOUTHWEST SKIN SPECIALISTS LLC | An Open-label Extension Study of ARGX-113-2009 to Evaluate the Long term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid | No dispute reported | 06/30/2026 | 1237157630 |
| Principal investigator 1 | ARGENX US, INC. | $1,168.76 | 11/05/2025 | Non-covered Recipient Entity SOUTHWEST SKIN SPECIALISTS LLC | An Open-label Extension Study of ARGX-113-2009 to Evaluate the Long term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid | No dispute reported | 06/30/2026 | 1237157647 |
| Principal investigator 1 | Incyte Corporation | $6,500.00 | 10/29/2025 | Non-covered Recipient Entity SOUTHWEST SKIN SPECIALISTS PHOENIX BILTMORE | Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib | No dispute reported | 06/30/2026 | 1240592811 |
| Principal investigator 1 | Incyte Corporation | $1,965.00 | 10/29/2025 | Non-covered Recipient Entity SOUTHWEST SKIN SPECIALISTS PHOENIX BILTMORE | Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib | No dispute reported | 06/30/2026 | 1240592815 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $657.00 | 10/27/2025 | Non-covered Recipient Entity US Dermatology Partners-Phoenix | A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy | No dispute reported | 06/30/2026 | 1220760123 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $12.00 | 10/27/2025 | Non-covered Recipient Entity US Dermatology Partners-Phoenix | A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy | No dispute reported | 06/30/2026 | 1220760125 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $109.25 | 10/27/2025 | Non-covered Recipient Entity US Dermatology Partners-Phoenix | A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy | No dispute reported | 06/30/2026 | 1220760127 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $50.70 | 10/27/2025 | Non-covered Recipient Entity US Dermatology Partners-Phoenix | A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy | No dispute reported | 06/30/2026 | 1220760129 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $50.70 | 10/27/2025 | Non-covered Recipient Entity US Dermatology Partners-Phoenix | A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy | No dispute reported | 06/30/2026 | 1220760131 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $50.70 | 10/27/2025 | Non-covered Recipient Entity US Dermatology Partners-Phoenix | A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy | No dispute reported | 06/30/2026 | 1220760133 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $50.70 | 10/27/2025 | Non-covered Recipient Entity US Dermatology Partners-Phoenix | A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy | No dispute reported | 06/30/2026 | 1220760135 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $117.30 | 10/27/2025 | Non-covered Recipient Entity US Dermatology Partners-Phoenix | A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy | No dispute reported | 06/30/2026 | 1220760137 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $17.50 | 10/27/2025 | Non-covered Recipient Entity US Dermatology Partners-Phoenix | A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy | No dispute reported | 06/30/2026 | 1220760139 |
| Principal investigator 1 | ARGENX US, INC. | $3,171.15 | 10/24/2025 | Non-covered Recipient Entity SOUTHWEST SKIN SPECIALISTS LLC | An Open-label Extension Study of ARGX-113-2009 to Evaluate the Long term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid | No dispute reported | 06/30/2026 | 1237157658 |
| Principal investigator 1 | Incyte Corporation | $11,323.50 | 10/22/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS PHOENIX | A Phase 3, Double-Blinded, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Prurigo Nodularis | No dispute reported | 06/30/2026 | 1240553788 |
| Principal investigator 1 | LEO Pharma AS | $411.00 | 10/20/2025 | Non-covered Recipient Entity SOUTHWEST SKIN SPECIALISTS LLC | TRACE STUDY: TRALOKINUMAB REAL WORLD CLINICAL USE: AN OBSERVATIONAL COHORT STUDY OF ATOPIC DERMATITIS PATIENTS PRESCRIBED TRALOKINUMAB | No dispute reported | 06/30/2026 | 1251993935 |
| Principal investigator 1 | ARGENX US, INC. | $2,750.00 | 10/17/2025 | Non-covered Recipient Entity SOUTHWEST SKIN SPECIALISTS LLC | An Open-label Extension Study of ARGX-113-2009 to Evaluate the Long term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid | No dispute reported | 06/30/2026 | 1237157634 |
| Principal investigator 1 | ARGENX US, INC. | $1,500.00 | 10/17/2025 | Non-covered Recipient Entity SOUTHWEST SKIN SPECIALISTS LLC | An Open-label Extension Study of ARGX-113-2009 to Evaluate the Long term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid | No dispute reported | 06/30/2026 | 1237157638 |
| Principal investigator 1 | ARGENX US, INC. | $1,100.00 | 10/17/2025 | Non-covered Recipient Entity SOUTHWEST SKIN SPECIALISTS LLC | An Open-label Extension Study of ARGX-113-2009 to Evaluate the Long term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid | No dispute reported | 06/30/2026 | 1237157643 |
| Principal investigator 1 | ARGENX US, INC. | $1,092.00 | 10/17/2025 | Non-covered Recipient Entity SOUTHWEST SKIN SPECIALISTS LLC | An Open-label Extension Study of ARGX-113-2009 to Evaluate the Long term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid | No dispute reported | 06/30/2026 | 1237157651 |
| Principal investigator 1 | ARGENX US, INC. | $2,500.00 | 10/17/2025 | Non-covered Recipient Entity SOUTHWEST SKIN SPECIALISTS LLC | An Open-label Extension Study of ARGX-113-2009 to Evaluate the Long term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid | No dispute reported | 06/30/2026 | 1237157655 |
| Principal investigator 1 | ARGENX US, INC. | $1,863.00 | 10/17/2025 | Non-covered Recipient Entity SOUTHWEST SKIN SPECIALISTS LLC | An Open-label Extension Study of ARGX-113-2009 to Evaluate the Long term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid | No dispute reported | 06/30/2026 | 1237157662 |
| Principal investigator 1 | ABBVIE INC. | $650.75 | 10/09/2025 | Non-covered Recipient Entity SOUTHWEST SKIN SPECIALISTS LLC | Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis | No dispute reported | 06/30/2026 | 1202514735 |
| Principal investigator 1 | ABBVIE INC. | $14,295.70 | 10/09/2025 | Non-covered Recipient Entity SOUTHWEST SKIN SPECIALISTS LLC | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202514737 |
| Principal investigator 1 | ABBVIE INC. | $5,484.00 | 10/09/2025 | Non-covered Recipient Entity SOUTHWEST SKIN SPECIALISTS LLC | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202514869 |
| Principal investigator 1 | Eli Lilly and Company | $14,000.00 | 10/07/2025 | Non-covered Recipient Entity SOUTHWEST SKIN SPECIALISTS LLC | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LEBRIKIZUMAB IN ADULT AND ADOLESCENT PARTICIPANTS WITH MODERATE-TO-SEVERE ATOPIC HAND AND FOOT DERMATITIS | No dispute reported | 06/30/2026 | 1187891296 |
| Principal investigator 1 | Eli Lilly and Company | $14,000.00 | 10/07/2025 | Non-covered Recipient Entity SOUTHWEST SKIN SPECIALISTS LLC | A PHASE 4, PROSPECTIVE, OPEN-LABEL, SINGLE ARM STUDY TO ASSESS THE EFFECTIVENESS OF TIRZEPATIDE AFTER INITIATION OF IXEKIZUMAB IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT IN CLINICAL PRACTICE | No dispute reported | 06/30/2026 | 1187891298 |
| Principal investigator 1 | Incyte Corporation | $2,288.00 | 10/02/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS PHOENIX | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240553758 |
| Principal investigator 1 | Incyte Corporation | $2,288.00 | 10/02/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS PHOENIX | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240553764 |
| Principal investigator 1 | Incyte Corporation | $2,421.00 | 10/02/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS PHOENIX | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240553817 |
| Principal investigator 1 | Incyte Corporation | $2,421.00 | 10/02/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS PHOENIX | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240553824 |
| Principal investigator 1 | Incyte Corporation | $542.30 | 10/02/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS PHOENIX | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240553835 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $9,147.74 | 10/01/2025 | Non-covered Recipient Entity SOUTHWEST SKIN SPECIALISTS LLC | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223286121 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,790.79 | 10/01/2025 | Non-covered Recipient Entity SOUTHWEST SKIN SPECIALISTS LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223286141 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $31.11 | 09/19/2025 | Non-covered Recipient Entity US Dermatology Partners-Phoenix | A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy | No dispute reported | 06/30/2026 | 1220813193 |
| Principal investigator 1 | ABBVIE INC. | $13,461.40 | 09/04/2025 | Non-covered Recipient Entity SOUTHWEST SKIN SPECIALISTS LLC | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202509510 |
| Principal investigator 1 | ABBVIE INC. | $1,386.50 | 09/04/2025 | Non-covered Recipient Entity SOUTHWEST SKIN SPECIALISTS LLC | Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis | No dispute reported | 06/30/2026 | 1202509620 |
| Principal investigator 1 | Incyte Corporation | $1,132.20 | 09/04/2025 | Non-covered Recipient Entity SOUTHWEST SKIN SPECIALISTS PHOENIX BILTMORE | Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib | No dispute reported | 06/30/2026 | 1240592807 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $10,000.00 | 09/04/2025 | Non-covered Recipient Entity Southwest Skin Specialists Llc | A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis | No dispute reported | 06/30/2026 | 1246434721 |
| Principal investigator 1 | ABBVIE INC. | $1,406.70 | 09/03/2025 | Non-covered Recipient Entity SOUTHWEST SKIN SPECIALISTS LLC | A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202507927 |
| Principal investigator 1 | ABBVIE INC. | $22,774.00 | 09/03/2025 | Non-covered Recipient Entity SOUTHWEST SKIN SPECIALISTS LLC | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202508028 |
| Principal investigator 1 | Incyte Corporation | $11.66 | 09/02/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS PHOENIX | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240553532 |
| Principal investigator 1 | Incyte Corporation | $135.40 | 09/02/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS PHOENIX | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240553562 |
| Principal investigator 1 | Incyte Corporation | $41.10 | 09/02/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS PHOENIX | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240553579 |
| Principal investigator 1 | Incyte Corporation | $41.10 | 09/02/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS PHOENIX | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240553584 |
| Principal investigator 1 | Incyte Corporation | $41.10 | 09/02/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS PHOENIX | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240553588 |
| Principal investigator 1 | Incyte Corporation | $41.10 | 09/02/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS PHOENIX | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240553593 |
| Principal investigator 1 | Incyte Corporation | $59.13 | 09/02/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS PHOENIX | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240553608 |
| Principal investigator 1 | ARGENX US, INC. | $1,928.52 | 08/27/2025 | Non-covered Recipient Entity SOUTHWEST SKIN SPECIALISTS LLC | An Open-label Extension Study of ARGX-113-2009 to Evaluate the Long term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid | No dispute reported | 06/30/2026 | 1237157621 |
| Principal investigator 1 | Incyte Corporation | $1,183.30 | 08/20/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS PHOENIX | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240553523 |
| Principal investigator 1 | Incyte Corporation | $375.00 | 08/20/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS PHOENIX | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240553528 |
| Principal investigator 1 | Incyte Corporation | $1,526.00 | 08/20/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS PHOENIX | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240553614 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,723.28 | 08/15/2025 | Non-covered Recipient Entity SOUTHWEST SKIN SPECIALISTS LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223284351 |
| Principal investigator 1 | ABBVIE INC. | $1,386.50 | 08/06/2025 | Non-covered Recipient Entity SOUTHWEST SKIN SPECIALISTS LLC | Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis | No dispute reported | 06/30/2026 | 1202503447 |
| Principal investigator 1 | ABBVIE INC. | $36,327.20 | 08/06/2025 | Non-covered Recipient Entity SOUTHWEST SKIN SPECIALISTS LLC | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202503551 |
| Principal investigator 1 | ABBVIE INC. | $17,411.00 | 08/05/2025 | Non-covered Recipient Entity SOUTHWEST SKIN SPECIALISTS LLC | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202502110 |
| Principal investigator 1 | Incyte Corporation | $2,199.60 | 08/04/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS PHOENIX | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240553537 |
| Principal investigator 1 | Incyte Corporation | $54.76 | 08/04/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS PHOENIX | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240553555 |
| Principal investigator 1 | Incyte Corporation | $98.72 | 08/04/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS PHOENIX | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240553567 |
| Principal investigator 1 | Incyte Corporation | $80.15 | 08/04/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS PHOENIX | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240553574 |
| Principal investigator 1 | Incyte Corporation | $32.36 | 08/04/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS PHOENIX | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240553620 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $3,549.77 | 08/01/2025 | Non-covered Recipient Entity SOUTHWEST SKIN SPECIALISTS LLC | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223283391 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $2,700.00 | 07/23/2025 | Non-covered Recipient Entity Southwest Skin Specialists Llc | Registry to characterize the patients who receive Dupixent for PN in a real-world setting | No dispute reported | 06/30/2026 | 1226094014 |
| Principal investigator 1 | Incyte Corporation | $2,291.40 | 07/22/2025 | Non-covered Recipient Entity SOUTHWEST SKIN SPECIALISTS PHOENIX BILTMORE | Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib | No dispute reported | 06/30/2026 | 1240592801 |
| Principal investigator 1 | Incyte Corporation | $1,131.30 | 07/18/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS PHOENIX | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240553543 |
| Principal investigator 1 | Incyte Corporation | $2,421.00 | 07/18/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS PHOENIX | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240553550 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $938.25 | 07/11/2025 | Non-covered Recipient Entity Southwest Skin Specialists Llc | Registry to characterize the patients who receive Dupixent for PN in a real-world setting | No dispute reported | 06/30/2026 | 1226094019 |
| Principal investigator 1 | Incyte Corporation | $2,264.40 | 07/10/2025 | Non-covered Recipient Entity SOUTHWEST SKIN SPECIALISTS PHOENIX BILTMORE | Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib | No dispute reported | 06/30/2026 | 1240592804 |
| Principal investigator 1 | Incyte Corporation | $1,528.20 | 07/09/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS PHOENIX | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240553599 |
| Principal investigator 1 | LEO Pharma AS | $1,000.00 | 07/07/2025 | Non-covered Recipient Entity SOUTHWEST SKIN SPECIALISTS LLC | TRACE STUDY: TRALOKINUMAB REAL WORLD CLINICAL USE: AN OBSERVATIONAL COHORT STUDY OF ATOPIC DERMATITIS PATIENTS PRESCRIBED TRALOKINUMAB | No dispute reported | 06/30/2026 | 1251993523 |
| Principal investigator 1 | ABBVIE INC. | $17,928.00 | 07/02/2025 | Non-covered Recipient Entity SOUTHWEST SKIN SPECIALISTS LLC | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202495837 |
| Principal investigator 1 | ABBVIE INC. | $1,406.70 | 07/02/2025 | Non-covered Recipient Entity SOUTHWEST SKIN SPECIALISTS LLC | A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202495839 |
| Principal investigator 1 | ABBVIE INC. | $15,181.20 | 07/02/2025 | Non-covered Recipient Entity SOUTHWEST SKIN SPECIALISTS LLC | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202495873 |
| Principal investigator 1 | UCB SA | $70.00 | 06/26/2025 | Non-covered Recipient Entity Perseverance Research Center | A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER, OUTPATIENT, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF STACCATO ALPRAZOLAM IN STUDY PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH STEREOTYPICAL PROLONGED SEIZURES | No dispute reported | 06/30/2026 | 1246658184 |
| Principal investigator 1 | Incyte Corporation | $375.00 | 06/25/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS PHOENIX | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240553282 |
| Principal investigator 1 | Incyte Corporation | $976.50 | 06/25/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS PHOENIX | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240553288 |
| Principal investigator 1 | Incyte Corporation | $1,649.00 | 06/25/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS PHOENIX | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240553294 |
| Principal investigator 1 | Incyte Corporation | $1,526.00 | 06/25/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS PHOENIX | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240553464 |
| Principal investigator 1 | Incyte Corporation | $1,526.00 | 06/25/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS PHOENIX | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240553470 |
| Principal investigator 1 | Incyte Corporation | $180.00 | 06/20/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS PHOENIX | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240553298 |
| Principal investigator 1 | Incyte Corporation | $2,503.71 | 06/13/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS PHOENIX | A Phase 3, Double-Blinded, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Prurigo Nodularis | No dispute reported | 06/30/2026 | 1240553210 |
| Principal investigator 1 | Incyte Corporation | $164.56 | 06/13/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS PHOENIX | A Phase 3, Double-Blinded, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Prurigo Nodularis | No dispute reported | 06/30/2026 | 1240553455 |
| Principal investigator 1 | Incyte Corporation | $2,193.00 | 06/11/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS PHOENIX | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240553336 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $6,937.28 | 06/11/2025 | Non-covered Recipient Entity SOUTHWEST SKIN SPECIALISTS LLC | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223281078 |
| Principal investigator 1 | Incyte Corporation | $1,528.20 | 06/06/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS PHOENIX | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240553322 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $15,000.00 | 06/05/2025 | Non-covered Recipient Entity Southwest Skin Specialists dba Medical Dermatology Specialists | A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy | No dispute reported | 06/30/2026 | 1220814617 |
| Principal investigator 1 | Amgen Inc. | $14,392.00 | 06/04/2025 | Non-covered Recipient Entity SOUTHWEST SKIN SPECIALISTS LLC | A Phase 3, Multicenter, Double-blind Maintenance Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASCEND) | No dispute reported | 06/30/2026 | 1246648528 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $3,446.56 | 06/04/2025 | Non-covered Recipient Entity SOUTHWEST SKIN SPECIALISTS LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223280714 |
| Principal investigator 1 | ABBVIE INC. | $1,840.73 | 06/03/2025 | Non-covered Recipient Entity SOUTHWEST SKIN SPECIALISTS LLC | A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202488179 |
| Principal investigator 1 | ABBVIE INC. | $4,213.50 | 06/03/2025 | Non-covered Recipient Entity SOUTHWEST SKIN SPECIALISTS LLC | Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis | No dispute reported | 06/30/2026 | 1202488181 |
| Principal investigator 1 | ABBVIE INC. | $26,433.00 | 06/03/2025 | Non-covered Recipient Entity SOUTHWEST SKIN SPECIALISTS LLC | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202488183 |
| Principal investigator 1 | ABBVIE INC. | $6,274.90 | 06/03/2025 | Non-covered Recipient Entity SOUTHWEST SKIN SPECIALISTS LLC | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202488185 |
| Principal investigator 1 | Incyte Corporation | $8.22 | 06/03/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS PHOENIX | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240553369 |
| Principal investigator 1 | Incyte Corporation | $0.31 | 06/03/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS PHOENIX | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240553396 |
| Principal investigator 1 | Incyte Corporation | $2.43 | 06/03/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS PHOENIX | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240553402 |
| Principal investigator 1 | Incyte Corporation | $8.22 | 06/03/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS PHOENIX | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240553409 |
| Principal investigator 1 | Incyte Corporation | $8.24 | 06/03/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS PHOENIX | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240553415 |
| Principal investigator 1 | Incyte Corporation | $11.45 | 06/03/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS PHOENIX | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240553421 |
| Principal investigator 1 | Incyte Corporation | $11.33 | 06/03/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS PHOENIX | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240553426 |
| Principal investigator 1 | Incyte Corporation | $91.60 | 06/03/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS PHOENIX | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240553432 |
| Principal investigator 1 | Incyte Corporation | $24.68 | 06/03/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS PHOENIX | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240553482 |
| Principal investigator 1 | Incyte Corporation | $8.22 | 06/03/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS PHOENIX | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240553514 |
| Principal investigator 1 | Incyte Corporation | $8.22 | 06/03/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS PHOENIX | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240553519 |
| Principal investigator 1 | PFIZER INC. | $2,695.00 | 05/30/2025 | Non-covered Recipient Entity Southwest Skin Specialists | A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF07264660 IN ADULT PARTICIPANTS WITH MODERATESEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1228763770 |
| Principal investigator 1 | ABBVIE INC. | $1,500.00 | 05/29/2025 | Non-covered Recipient Entity SOUTHWEST SKIN SPECIALISTS LLC | A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy | No dispute reported | 06/30/2026 | 1202486871 |
| Principal investigator 1 | Eli Lilly and Company | $2,471.11 | 05/27/2025 | Non-covered Recipient Entity ADVANCED MEDICAL RESEARCH LLC | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LEBRIKIZUMAB IN ADULT AND ADOLESCENT PARTICIPANTS WITH MODERATE-TO-SEVERE ATOPIC HAND AND FOOT DERMATITIS | No dispute reported | 06/30/2026 | 1187875715 |
| Principal investigator 1 | ARGENX US, INC. | $1,500.00 | 05/21/2025 | Non-covered Recipient Entity SOUTHWEST SKIN SPECIALISTS LLC | A Phase 2/3, Randomized, Double-Blinded, Placebo Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid | No dispute reported | 06/30/2026 | 1237157587 |
| Principal investigator 1 | ARGENX US, INC. | $750.00 | 05/21/2025 | Non-covered Recipient Entity SOUTHWEST SKIN SPECIALISTS LLC | A Phase 2/3, Randomized, Double-Blinded, Placebo Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid | No dispute reported | 06/30/2026 | 1237157590 |
| Principal investigator 1 | ARGENX US, INC. | $1,100.00 | 05/21/2025 | Non-covered Recipient Entity SOUTHWEST SKIN SPECIALISTS LLC | A Phase 2/3, Randomized, Double-Blinded, Placebo Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid | No dispute reported | 06/30/2026 | 1237157594 |
| Principal investigator 1 | ARGENX US, INC. | $3,250.00 | 05/21/2025 | Non-covered Recipient Entity SOUTHWEST SKIN SPECIALISTS LLC | A Phase 2/3, Randomized, Double-Blinded, Placebo Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid | No dispute reported | 06/30/2026 | 1237157599 |
| Principal investigator 1 | ARGENX US, INC. | $4,031.84 | 05/21/2025 | Non-covered Recipient Entity SOUTHWEST SKIN SPECIALISTS LLC | A Phase 2/3, Randomized, Double-Blinded, Placebo Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid | No dispute reported | 06/30/2026 | 1237157607 |
| Principal investigator 1 | ARGENX US, INC. | $2,184.00 | 05/21/2025 | Non-covered Recipient Entity SOUTHWEST SKIN SPECIALISTS LLC | A Phase 2/3, Randomized, Double-Blinded, Placebo Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid | No dispute reported | 06/30/2026 | 1237157611 |
| Principal investigator 1 | ARGENX US, INC. | $2,000.00 | 05/21/2025 | Non-covered Recipient Entity SOUTHWEST SKIN SPECIALISTS LLC | A Phase 2/3, Randomized, Double-Blinded, Placebo Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid | No dispute reported | 06/30/2026 | 1237157615 |
| Principal investigator 1 | ARGENX US, INC. | $147.15 | 05/21/2025 | Non-covered Recipient Entity SOUTHWEST SKIN SPECIALISTS LLC | A Phase 2/3, Randomized, Double-Blinded, Placebo Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid | No dispute reported | 06/30/2026 | 1237157618 |
| Principal investigator 1 | Incyte Corporation | $1,526.00 | 05/21/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS PHOENIX | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240553227 |
| Principal investigator 1 | Incyte Corporation | $1,568.50 | 05/21/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS PHOENIX | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240553239 |
| Principal investigator 1 | Incyte Corporation | $1,526.00 | 05/21/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS PHOENIX | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240553486 |
| Principal investigator 1 | Incyte Corporation | $1,526.00 | 05/21/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS PHOENIX | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240553492 |
| Principal investigator 1 | Incyte Corporation | $1,526.00 | 05/21/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS PHOENIX | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240553497 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $1,025.00 | 05/19/2025 | Non-covered Recipient Entity Oliver Street Dermatology Managemen U S Dermatology Partners Southwest Skin Specialists Llc | A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel Group, Proof-of-concept Study Assessing the Efficacy and Safety of Amlitelimab in Adult Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1226156460 |
| Principal investigator 1 | Incyte Corporation | $1,132.20 | 05/15/2025 | Non-covered Recipient Entity SOUTHWEST SKIN SPECIALISTS PHOENIX BILTMORE | Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib | No dispute reported | 06/30/2026 | 1240592798 |
| Principal investigator 1 | ABBVIE INC. | $18,068.95 | 05/07/2025 | Non-covered Recipient Entity SOUTHWEST SKIN SPECIALISTS LLC | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202482771 |
| Principal investigator 1 | Incyte Corporation | $2,444.00 | 05/07/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS PHOENIX | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240553251 |
| Principal investigator 1 | Incyte Corporation | $1,293.70 | 05/07/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS PHOENIX | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240553476 |
| Principal investigator 1 | ABBVIE INC. | $14,859.00 | 05/06/2025 | Non-covered Recipient Entity SOUTHWEST SKIN SPECIALISTS LLC | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202481451 |
| Principal investigator 1 | Incyte Corporation | $57.25 | 05/02/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS PHOENIX | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240553197 |
| Principal investigator 1 | Incyte Corporation | $2,288.00 | 05/02/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS PHOENIX | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240553246 |
| Principal investigator 1 | Incyte Corporation | $1,649.00 | 05/02/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS PHOENIX | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240553257 |
| Principal investigator 1 | Incyte Corporation | $1,620.30 | 05/02/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS PHOENIX | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240553263 |
| Principal investigator 1 | Incyte Corporation | $1,649.00 | 05/02/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS PHOENIX | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240553507 |
| Principal investigator 1 | ARGENX US, INC. | $3,171.15 | 05/01/2025 | Non-covered Recipient Entity SOUTHWEST SKIN SPECIALISTS LLC | An Open-label Extension Study of ARGX-113-2009 to Evaluate the Long term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid | No dispute reported | 06/30/2026 | 1237157602 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $31.11 | 04/15/2025 | Non-covered Recipient Entity US Dermatology Partners-Phoenix | A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy | No dispute reported | 06/30/2026 | 1220813191 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $938.25 | 04/11/2025 | Non-covered Recipient Entity Southwest Skin Specialists Llc | Registry to characterize the patients who receive Dupixent for PN in a real-world setting | No dispute reported | 06/30/2026 | 1226093991 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $3,755.00 | 04/11/2025 | Non-covered Recipient Entity SOUTHWEST SKIN SPECIALISTS LLC | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223277836 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $5,056.66 | 04/11/2025 | Non-covered Recipient Entity SOUTHWEST SKIN SPECIALISTS LLC | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223278048 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $25,236.18 | 04/09/2025 | Non-covered Recipient Entity Southwest Skin Specialists Llc | A Study to Evaluate Effectiveness and Safety of Deucravacitinib in Participants With Non-Pustular Palmoplantar and Genital Psoriasis | No dispute reported | 06/30/2026 | 1235993559 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $5,687.56 | 04/09/2025 | Non-covered Recipient Entity SOUTHWEST SKIN SPECIALISTS LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223277754 |
| Principal investigator 1 | Incyte Corporation | $1,528.20 | 04/07/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS PHOENIX | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240553233 |
| Principal investigator 1 | Incyte Corporation | $1,929.60 | 04/07/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS PHOENIX | A Phase 3, Double-Blinded, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Prurigo Nodularis | No dispute reported | 06/30/2026 | 1240553438 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $1,025.00 | 04/07/2025 | Non-covered Recipient Entity Oliver Street Dermatology Managemen U S Dermatology Partners Southwest Skin Specialists Llc | A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel Group, Proof-of-concept Study Assessing the Efficacy and Safety of Amlitelimab in Adult Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1226156400 |
| Principal investigator 1 | ABBVIE INC. | $18,911.00 | 04/03/2025 | Non-covered Recipient Entity SOUTHWEST SKIN SPECIALISTS LLC | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202473841 |
| Principal investigator 1 | ABBVIE INC. | $24,046.80 | 04/03/2025 | Non-covered Recipient Entity SOUTHWEST SKIN SPECIALISTS LLC | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202473846 |
| Principal investigator 1 | ABBVIE INC. | $2,062.10 | 04/03/2025 | Non-covered Recipient Entity SOUTHWEST SKIN SPECIALISTS LLC | A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy | No dispute reported | 06/30/2026 | 1202474309 |
| Principal investigator 1 | Incyte Corporation | $954.50 | 04/02/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS PHOENIX | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240553203 |
| Principal investigator 1 | Incyte Corporation | $1,526.00 | 04/02/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS PHOENIX | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240553217 |
| Principal investigator 1 | Incyte Corporation | $375.00 | 04/02/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS PHOENIX | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240553223 |
| Principal investigator 1 | Incyte Corporation | $21.20 | 04/02/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS PHOENIX | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240553268 |
| Principal investigator 1 | Incyte Corporation | $26.90 | 04/02/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS PHOENIX | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240553276 |
| Principal investigator 1 | Incyte Corporation | $43.04 | 04/02/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS PHOENIX | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240553304 |
| Principal investigator 1 | Incyte Corporation | $32.28 | 04/02/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS PHOENIX | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240553311 |
| Principal investigator 1 | Incyte Corporation | $26.90 | 04/02/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS PHOENIX | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240553315 |
| Principal investigator 1 | Incyte Corporation | $84.80 | 04/02/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS PHOENIX | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240553328 |
| Principal investigator 1 | Incyte Corporation | $58.30 | 04/02/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS PHOENIX | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240553343 |
| Principal investigator 1 | Incyte Corporation | $132.50 | 04/02/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS PHOENIX | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240553349 |
| Principal investigator 1 | Incyte Corporation | $201.40 | 04/02/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS PHOENIX | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240553355 |
| Principal investigator 1 | Incyte Corporation | $53.00 | 04/02/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS PHOENIX | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240553361 |
| Principal investigator 1 | Incyte Corporation | $397.50 | 04/02/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS PHOENIX | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240553378 |
| Principal investigator 1 | Incyte Corporation | $376.30 | 04/02/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS PHOENIX | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240553385 |
| Principal investigator 1 | Incyte Corporation | $47.70 | 04/02/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS PHOENIX | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240553391 |
| Principal investigator 1 | Incyte Corporation | $2,288.00 | 04/02/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS PHOENIX | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240553443 |
| Principal investigator 1 | Incyte Corporation | $328.60 | 04/02/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS PHOENIX | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240553450 |
| Principal investigator 1 | Incyte Corporation | $32.28 | 04/02/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS PHOENIX | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240553501 |
| Principal investigator 1 | Eli Lilly and Company | $20,564.00 | 03/18/2025 | Non-covered Recipient Entity SOUTHWEST SKIN SPECIALISTS LLC | AN OPEN-LABEL, STUDY TO EVALUATE THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN ADULT AND ADOLESCENT PARTICIPANTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS PREVIOUSLY TREATED WITH DUPILUMAB | No dispute reported | 06/30/2026 | 1187888916 |
| Principal investigator 1 | ABBVIE INC. | $5,931.90 | 03/13/2025 | Non-covered Recipient Entity SOUTHWEST SKIN SPECIALISTS LLC | M23-698 - A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202463282 |
| Principal investigator 1 | Incyte Corporation | $1,114.00 | 03/12/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS PHOENIX | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240552961 |
| Principal investigator 1 | Incyte Corporation | $1,698.00 | 03/12/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS PHOENIX | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240553001 |
| Principal investigator 1 | Incyte Corporation | $2,444.00 | 03/12/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS PHOENIX | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240553163 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $3,190.80 | 03/10/2025 | Non-covered Recipient Entity Oliver Street Dermatology Managemen U S Dermatology Partners Southwest Skin Specialists Llc | A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel Group, Proof-of-concept Study Assessing the Efficacy and Safety of Amlitelimab in Adult Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1226156404 |
| Principal investigator 1 | ABBVIE INC. | $22,634.60 | 03/07/2025 | Non-covered Recipient Entity SOUTHWEST SKIN SPECIALISTS LLC | M20-465 - A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202460400 |
| Principal investigator 1 | ABBVIE INC. | $1,489.06 | 03/07/2025 | Non-covered Recipient Entity SOUTHWEST SKIN SPECIALISTS LLC | M16-047 - A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202460404 |
| Principal investigator 1 | ABBVIE INC. | $4,672.50 | 03/07/2025 | Non-covered Recipient Entity SOUTHWEST SKIN SPECIALISTS LLC | M23-702 - Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis | No dispute reported | 06/30/2026 | 1202460408 |
| Principal investigator 1 | ABBVIE INC. | $1,360.50 | 03/06/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS PC | M18-891 - A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2) | No dispute reported | 06/30/2026 | 1202457236 |
| Principal investigator 1 | ABBVIE INC. | $9,527.00 | 03/06/2025 | Non-covered Recipient Entity SOUTHWEST SKIN SPECIALISTS LLC | M23-698 - A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202457481 |
| Principal investigator 1 | Incyte Corporation | $1,373.40 | 03/03/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS PHOENIX | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240553008 |
| Principal investigator 1 | Incyte Corporation | $32.36 | 03/03/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS PHOENIX | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240553094 |
| Principal investigator 1 | Incyte Corporation | $4.86 | 03/03/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS PHOENIX | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240553100 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,625.00 | 03/03/2025 | Non-covered Recipient Entity SOUTHWEST SKIN SPECIALISTS LLC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175423065 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $4,666.97 | 02/26/2025 | Non-covered Recipient Entity SOUTHWEST SKIN SPECIALISTS LLC | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223275659 |
| Principal investigator 1 | Incyte Corporation | $1,358.40 | 02/19/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS PHOENIX | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240552950 |
| Principal investigator 1 | Incyte Corporation | $1,698.00 | 02/19/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS PHOENIX | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240552955 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $1,239.00 | 02/18/2025 | Non-covered Recipient Entity Oliver Street Dermatology Managemen U S Dermatology Partners Southwest Skin Specialists Llc | A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel Group, Proof-of-concept Study Assessing the Efficacy and Safety of Amlitelimab in Adult Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1226156392 |
| Principal investigator 1 | ARGENX US, INC. | $1,433.70 | 02/12/2025 | Non-covered Recipient Entity SOUTHWEST SKIN SPECIALISTS LLC | An Open-label Extension Study of ARGX-113-2009 to Evaluate the Long term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid | No dispute reported | 06/30/2026 | 1237157666 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,408.00 | 02/07/2025 | Non-covered Recipient Entity SOUTHWEST SKIN SPECIALISTS LLC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175423060 |
| Principal investigator 1 | ABBVIE INC. | $24,512.06 | 02/06/2025 | Non-covered Recipient Entity SOUTHWEST SKIN SPECIALISTS LLC | M20-465 - A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202449238 |
| Principal investigator 1 | Incyte Corporation | $1.96 | 02/06/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS PHOENIX | A Phase 3, Double-Blinded, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Prurigo Nodularis | No dispute reported | 06/30/2026 | 1240553157 |
| Principal investigator 1 | ABBVIE INC. | $268.25 | 02/05/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS PC | M18-891 - A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2) | No dispute reported | 06/30/2026 | 1202445452 |
| Principal investigator 1 | ABBVIE INC. | $19,221.00 | 02/05/2025 | Non-covered Recipient Entity SOUTHWEST SKIN SPECIALISTS LLC | M23-698 - A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202445633 |
| Principal investigator 1 | Eli Lilly and Company | $57,341.00 | 02/05/2025 | Non-covered Recipient Entity SOUTHWEST SKIN SPECIALISTS LLC | A PHASE 2B, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE ELTREKIBART IN ADULT PARTICIPANTS WITH MODERATE TO SEVERE HIDRADENITIS SUPPURATIVA | No dispute reported | 06/30/2026 | 1187890918 |
| Principal investigator 1 | Incyte Corporation | $1,894.00 | 02/05/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS PHOENIX | A Phase 3, Double-Blinded, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Prurigo Nodularis | No dispute reported | 06/30/2026 | 1240552945 |
| Principal investigator 1 | Incyte Corporation | $1,515.20 | 02/05/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS PHOENIX | A Phase 3, Double-Blinded, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Prurigo Nodularis | No dispute reported | 06/30/2026 | 1240553151 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,230.41 | 02/03/2025 | Non-covered Recipient Entity SOUTHWEST SKIN SPECIALISTS LLC | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223274697 |
| Principal investigator 1 | Amgen Inc. | $6,560.00 | 01/30/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS | A Phase 3, Randomized, 24-week, Placebo-controlled, Double-blind Study to Assess the Efficacy, Safety and Tolerability of Rocatinlimab (AMG 451) Monotherapy in Adult Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Horizon) | No dispute reported | 06/30/2026 | 1246644175 |
| Principal investigator 1 | Eli Lilly and Company | $82,990.00 | 01/28/2025 | Non-covered Recipient Entity SOUTHWEST SKIN SPECIALISTS LLC | EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSO) | No dispute reported | 06/30/2026 | 1187889852 |
| Principal investigator 1 | Amgen Inc. | $12,681.92 | 01/27/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS | A Phase 3, Multicenter, Double-blind Maintenance Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASCEND) | No dispute reported | 06/30/2026 | 1246644172 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $6.64 | 01/27/2025 | Non-covered Recipient Entity US Dermatology Partners-Phoenix | A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy | No dispute reported | 06/30/2026 | 1220760095 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $46.64 | 01/27/2025 | Non-covered Recipient Entity US Dermatology Partners-Phoenix | A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy | No dispute reported | 06/30/2026 | 1220760097 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $19.98 | 01/27/2025 | Non-covered Recipient Entity US Dermatology Partners-Phoenix | A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy | No dispute reported | 06/30/2026 | 1220760099 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $474.50 | 01/27/2025 | Non-covered Recipient Entity US Dermatology Partners-Phoenix | A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy | No dispute reported | 06/30/2026 | 1220760101 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4.80 | 01/27/2025 | Non-covered Recipient Entity US Dermatology Partners-Phoenix | A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy | No dispute reported | 06/30/2026 | 1220760103 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $87.40 | 01/27/2025 | Non-covered Recipient Entity US Dermatology Partners-Phoenix | A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy | No dispute reported | 06/30/2026 | 1220760105 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $30.42 | 01/27/2025 | Non-covered Recipient Entity US Dermatology Partners-Phoenix | A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy | No dispute reported | 06/30/2026 | 1220760107 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $30.42 | 01/27/2025 | Non-covered Recipient Entity US Dermatology Partners-Phoenix | A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy | No dispute reported | 06/30/2026 | 1220760109 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $30.42 | 01/27/2025 | Non-covered Recipient Entity US Dermatology Partners-Phoenix | A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy | No dispute reported | 06/30/2026 | 1220760111 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $30.42 | 01/27/2025 | Non-covered Recipient Entity US Dermatology Partners-Phoenix | A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy | No dispute reported | 06/30/2026 | 1220760113 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $19.54 | 01/27/2025 | Non-covered Recipient Entity US Dermatology Partners-Phoenix | A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy | No dispute reported | 06/30/2026 | 1220760115 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $23.84 | 01/27/2025 | Non-covered Recipient Entity US Dermatology Partners-Phoenix | A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy | No dispute reported | 06/30/2026 | 1220760117 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $62.56 | 01/27/2025 | Non-covered Recipient Entity US Dermatology Partners-Phoenix | A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy | No dispute reported | 06/30/2026 | 1220760119 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $11.00 | 01/27/2025 | Non-covered Recipient Entity US Dermatology Partners-Phoenix | A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy | No dispute reported | 06/30/2026 | 1220760121 |
| Principal investigator 1 | Incyte Corporation | $2,288.00 | 01/27/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS PHOENIX | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240552968 |
| Principal investigator 1 | Incyte Corporation | $839.40 | 01/27/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS PHOENIX | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240552974 |
| Principal investigator 1 | Incyte Corporation | $1,526.00 | 01/27/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS PHOENIX | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240552980 |
| Principal investigator 1 | Incyte Corporation | $1,526.00 | 01/27/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS PHOENIX | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240553173 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,723.28 | 01/22/2025 | Non-covered Recipient Entity SOUTHWEST SKIN SPECIALISTS LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223274379 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $2,836.00 | 01/21/2025 | Non-covered Recipient Entity Oliver Street Dermatology Managemen U S Dermatology Partners Southwest Skin Specialists Llc | A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel Group, Proof-of-concept Study Assessing the Efficacy and Safety of Amlitelimab in Adult Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1226156377 |
| Principal investigator 1 | Incyte Corporation | $989.80 | 01/17/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS PHOENIX | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240552931 |
| Principal investigator 1 | Incyte Corporation | $1,698.00 | 01/17/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS PHOENIX | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240552936 |
| Principal investigator 1 | Incyte Corporation | $1,843.00 | 01/17/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS PHOENIX | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240553137 |
| Principal investigator 1 | Incyte Corporation | $1,843.00 | 01/17/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS PHOENIX | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240553143 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $2,706.50 | 01/16/2025 | Non-covered Recipient Entity Southwest Skin Specialists Llc | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Effect of Deucravacitinib on Quality of Life in Participants With Plaque Psoriasis in a Community Setting | No dispute reported | 06/30/2026 | 1235993561 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $7,440.40 | 01/15/2025 | Non-covered Recipient Entity US Dermatology Partners-Phoenix | A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy | No dispute reported | 06/30/2026 | 1220760093 |
| Principal investigator 1 | Eli Lilly and Company | $3,603.29 | 01/15/2025 | Non-covered Recipient Entity ADVANCED MEDICAL RESEARCH LLC | EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSO) | No dispute reported | 06/30/2026 | 1187874129 |
| Principal investigator 1 | Incyte Corporation | $1,526.00 | 01/15/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS PHOENIX | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240552904 |
| Principal investigator 1 | Incyte Corporation | $1,649.00 | 01/15/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS PHOENIX | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240552921 |
| Principal investigator 1 | Incyte Corporation | $1,708.80 | 01/15/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS PHOENIX | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240552924 |
| Principal investigator 1 | Incyte Corporation | $1,526.00 | 01/15/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS PHOENIX | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240553167 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $1,876.50 | 01/15/2025 | Non-covered Recipient Entity Southwest Skin Specialists Llc | Registry to characterize the patients who receive Dupixent for PN in a real-world setting | No dispute reported | 06/30/2026 | 1226093979 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $210.60 | 01/15/2025 | Non-covered Recipient Entity Southwest Skin Specialists Llc | Registry to characterize the patients who receive Dupixent for PN in a real-world setting | No dispute reported | 06/30/2026 | 1226093986 |
| Principal investigator 1 | ARGENX US, INC. | $9,115.57 | 01/10/2025 | Non-covered Recipient Entity SOUTHWEST SKIN SPECIALISTS LLC | A Phase 2/3, Randomized, Double-Blinded, Placebo Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid | No dispute reported | 06/30/2026 | 1237157671 |
| Principal investigator 1 | Incyte Corporation | $1,515.20 | 01/10/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS PHOENIX | A Phase 3, Double-Blinded, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Prurigo Nodularis | No dispute reported | 06/30/2026 | 1240552909 |
| Principal investigator 1 | Incyte Corporation | $1,894.00 | 01/10/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS PHOENIX | A Phase 3, Double-Blinded, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Prurigo Nodularis | No dispute reported | 06/30/2026 | 1240552915 |
| Principal investigator 1 | UCB SA | $63,375.00 | 01/03/2025 | Non-covered Recipient Entity US DERMATOLOGY PARTNERS PHOENIX 7TH ST | A Phase 3, open-label, parallel group, multicenter, extension study evaluating the long-term treatment of bimekizumab in study participants with moderate to severe hidradenitis suppurativa | No dispute reported | 06/30/2026 | 1246656244 |
| Principal investigator 1 | ABBVIE INC. | $1,360.50 | 01/02/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS PC | M18-891 - A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2) | No dispute reported | 06/30/2026 | 1202435376 |
| Principal investigator 1 | ABBVIE INC. | $601.43 | 01/02/2025 | Non-covered Recipient Entity SOUTHWEST SKIN SPECIALISTS LLC | M16-047 - A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202435653 |
| Principal investigator 1 | Incyte Corporation | $19.44 | 01/02/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS PHOENIX | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240552986 |
| Principal investigator 1 | Incyte Corporation | $4.86 | 01/02/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS PHOENIX | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240552992 |
| Principal investigator 1 | Incyte Corporation | $45.80 | 01/02/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS PHOENIX | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240552996 |
| Principal investigator 1 | Incyte Corporation | $64.72 | 01/02/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS PHOENIX | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240553014 |
| Principal investigator 1 | Incyte Corporation | $68.70 | 01/02/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS PHOENIX | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240553024 |
| Principal investigator 1 | Incyte Corporation | $114.50 | 01/02/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS PHOENIX | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240553030 |
| Principal investigator 1 | Incyte Corporation | $10.60 | 01/02/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS PHOENIX | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240553035 |
| Principal investigator 1 | Incyte Corporation | $32.36 | 01/02/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS PHOENIX | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240553042 |
| Principal investigator 1 | Incyte Corporation | $64.72 | 01/02/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS PHOENIX | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240553048 |
| Principal investigator 1 | Incyte Corporation | $14.84 | 01/02/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS PHOENIX | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240553053 |
| Principal investigator 1 | Incyte Corporation | $41.10 | 01/02/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS PHOENIX | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240553061 |
| Principal investigator 1 | Incyte Corporation | $20.60 | 01/02/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS PHOENIX | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240553066 |
| Principal investigator 1 | Incyte Corporation | $28.84 | 01/02/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS PHOENIX | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240553073 |
| Principal investigator 1 | Incyte Corporation | $74.04 | 01/02/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS PHOENIX | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240553078 |
| Principal investigator 1 | Incyte Corporation | $48.54 | 01/02/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS PHOENIX | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240553083 |
| Principal investigator 1 | Incyte Corporation | $24.68 | 01/02/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS PHOENIX | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240553088 |
| Principal investigator 1 | Incyte Corporation | $91.60 | 01/02/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS PHOENIX | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240553107 |
| Principal investigator 1 | Incyte Corporation | $24.66 | 01/02/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS PHOENIX | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240553112 |
| Principal investigator 1 | Incyte Corporation | $24.66 | 01/02/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS PHOENIX | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240553118 |
| Principal investigator 1 | Incyte Corporation | $24.66 | 01/02/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS PHOENIX | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240553126 |
| Principal investigator 1 | Incyte Corporation | $24.66 | 01/02/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS PHOENIX | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240553132 |
| Principal investigator 1 | Incyte Corporation | $41.10 | 01/02/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS PHOENIX | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240553180 |
| Principal investigator 1 | Incyte Corporation | $41.10 | 01/02/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS PHOENIX | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240553186 |
| Principal investigator 1 | Incyte Corporation | $41.10 | 01/02/2025 | Non-covered Recipient Entity MEDICAL DERMATOLOGY SPECIALISTS PHOENIX | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240553193 |